Results 31 to 40 of about 4,977 (213)

The double bronchodilation era: new capabilities in a new drug delivery device

Медицинский совет, 2022
A literature review presents the efficacy and safety of the new glycopyrronium bromide/formoterol fumarate (GP/FF) combination in the treatment of patients with chronic obstructive pulmonary disease according to the PINNACLE 1, 2, 3, 4 studies. There are
E. A. Orlova, I. P. Dorfman, M. A. Orlov, M. A. Abdullaev   +3 more
doaj   +1 more source

The influence of basic treatment with tiotropium bromide of patients with chronic obstructive pulmonary disease stage II on the morpho-functional state of bronchial mucosa and the level of type IV collagen in bronchoalveolar lavage fluid.

Galician Medical Journal, 2018
The objective of the research was to evaluate the influence of basic treatment of patients with chronic obstructive pulmonary disease with tiotropium bromide on the processes of morphological rearrangement and local barrier defence mechanisms in the ...
Mykola Osyrovskyy, Mariana Olegivna Kulynych-Miskiv, Iryna Savelikhina, Valentina Goncharuk, Ksenia Ostrovska   +4 more
doaj   +1 more source

Tiotropium/Olodaterol treatment reduces cigarette smoke extract-induced cell death in BEAS-2B bronchial epithelial cells

BMC Pharmacology and Toxicology, 2020
Background Cigarette smoking is a critical risk factor for the destruction of lung parenchyma or the development of emphysema, which is characteristic of COPD.
Cheng-hsiung Chen, Yi-Rong Li, Sheng-Hao Lin, Hsiu-Hui Chang, Woei-Horng Chai, Po-Chiang Chan, Ching-Hsiung Lin   +6 more
doaj   +1 more source

Pharmacoeconomic analysis of the use of a fixed combination of tiotropium bromide and olodaterol as maintenance therapy in patients with chronic obstructive pulmonary disease in the Russian Federation

Фармакоэкономика, 2022
Objective: to evaluate the pharmacoeconomic effectiveness of the use of a fixed double combination of tiotropium bromide + olodаterol in order to treat chronic obstructive pulmonary disease (COPD) in comparison with less expensive monotherapy with long ...
S. К. Zyryanov, I. N. Dyakov
doaj   +1 more source

Quantitative Analysis of Muscarinic Antagonist Atropine and Tiotropium in Microvolume Plasma Using Liquid Chromatography-Mass Spectrometry: Application for Pharmacokinetic Studies. [PDF]

J Anal Methods Chem
Despite the availability of current resources, the development of medical countermeasures remains crucial in combatting the threat posed by chemical warfare agents, such as organophosphorus compounds (OPs), which are toxic nerve agents requiring rapid medical intervention.
Trancart M, Penot M, Meesemaecker G, Boffy R, Hanak AS, Calas AG, Taudon N.   +6 more
europepmc   +2 more sources

Long-acting beta(2)-agonist in addition to tiotropium versus either tiotropium or long-acting beta(2)-agonist alone for chronic obstructive pulmonary disease [PDF]

, 2012
BackgroundLong-acting bronchodilators comprising long-acting beta(2)-agonists and the anticholinergic agent tiotropium are commonly used for managing persistent symptoms of chronic obstructive pulmonary disease.
Aaron, Aaron, Appleton, Arievich, Barr, Bateman, Berger, Brusasco, Calverley, Cazzola, Cheyne, Effing, Fujimoto, Gross, Hacken, Higgins, Hutchinson, Johnson, Kaplan, Karner, Lacasse, Mahler, Mahler, Marco, Meer, Meyer, Najafzadeh, Najafzadeh, New, Noord, Noord, Noord, Proskocil, Rodrigo, Roisman, Singh, Tanaka, Tashkin, Tashkin, Tashkin, Tashkin, Tashkin, Tashkin, Tashkin, Vogelmeier, Vogelmeier, Wallukat, Welsh   +47 more
core   +1 more source

Clinical and economic evaluation of using fixed dose dual bronchodilator combination tiotropiumolodaterol in patients with chronic obstructive pulmonary disease

Медицинский совет, 2018
The paper is devoted to the problem of clinical efficacy and pharmacoeconomic evaluation of Spiolto Respimat. The results of clinical trials prove that Spiolto Respimat in patients with COPD improves spirometric values, symptoms of dyspnea and health ...
S. K. Zyryanov, Y. A. Galatonova
doaj   +1 more source

The lung function profile of once-daily tiotropium and olodaterol via Respimat® is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler® (ENERGITO® study) [PDF]

, 2016
Background: Tiotropium + olodaterol has demonstrated improvements beyond lung function benefits in a large Phase III clinical program as a once-daily maintenance treatment for COPD and may be a potential option for the initiation of maintenance treatment
Beeh, Kai-Michael, Bjermer, Leif,, Derom, Eric, Echave-Sustaeta, José, Grönke, Lars, Hamilton, Alan, Lund University., Lund University., Zhai, Dongmei   +8 more
core   +2 more sources

Skin reaction to inhaled tiotropium bromide: a case report

Journal of Medical Case Reports, 2011
Introduction Systemic reactions to inhaled drugs are rare. To the best of our knowledge, we report the first case of generalized itching related to the use of tiotropium bromide, a long acting inhaled anti-cholinergic agent commonly used to treat chronic
Megali Raffaella, Fuiano Nicola, Incorvaia Cristoforo, Riario-Sforza Gian   +3 more
doaj   +1 more source

Efficacy of tiotropium-olodaterol fixed-dose combination in COPD [PDF]

, 2016
Tiotropium-olodaterol, formulated in the Respimat soft-mist inhaler, is an inhaled fixed-dose combination (FDC) of a long-acting muscarinic antagonist (LAMA) and a long-acting beta(2)-agonist (LABA), commercialized under the name of Spiolto or Stiolto ...
Brusselle, Guy, Derom, Eric, Joos, Guy
core   +1 more source